St. Jude Care & Treatment

Menu

Close

Recruiting

ACNS1821: Selinexor and Radiation for Diffuse Intrinsic Pontine Glioma and High-Grade Glioma

About this study

We hope to learn how well a medicine called selinexor, given with radiation therapy, treats diffuse intrinsic pontine glioma (DIPG), also known as diffuse midline glioma (DMG), H3 K27M-mutant; high-grade glioma (HGG) with a genetic change called H3 K27M; and HGG without the genetic change.

We will study the use of this combined therapy to treat children and young adults with these cancers. This study has 2 parts (or phases):

  • The first part of this study is complete. We found the highest dose of selinexor that we can use to safely treat these patients.
  • In the second part of this study, we will find out how well selinexor and radiation therapy treat DIPG or HGG in children and young adults. We will also study the side effects of this treatment.

Eligibility overview

To take part in this study, you must:

  • Have DIPG or HGG
  • Be 12 months to 21 years old
  • Be enrolled in APEC14B1

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Study goal:

The first part of this study is complete. The second part (phase 2) aims to study how well selinexor works with radiation to treat DIPG and HGG.

Diagnosis:

Diffuse intrinsic pontine glioma, also known as diffuse midline glioma, H3 K27M-mutant; High-grade glioma (HGG) with H3K27M; HGG with wild-type H3K27M, and no mutation in BRAF V600E or IDH

Age:

12 months to 21 years

Clinical trials categories:

Diffuse Midline Glioma

Childhood Cancer Diffuse Intrinsic Pontine Glioma (DIPG) High-Grade Glioma Brain Tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more